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Introduction 
 Over the past several decades the United States has been experiencing an epidemic of 
prescription and non-prescription opioid use. The WHO World Drug Report found that in 2014 
there were an estimated 33 million opioid users world-wide, including about 15.6 million users 
of non-medical prescription opioids and 17.4 million opium and heroin users1. In the USA, 
approximately 2 million people had a substance use disorder involving prescription opioids in 
2015, while 591,000 had a heroin use disorder2. This same year over 20,000 Americans died of a 
prescription opioid overdose and nearly 13,000 died of a heroin overdose. These rates have 
increased rapidly in recent years; from 1999 to 2014 they nearly tripled, and from 2014 to 2015 
overdose deaths due to prescription opioids increased by 72.2%, while heroin overdoses 
increased by 20.6%3. These increased rates of heroin and prescription opioid use and overdose 
have been found throughout the country, though the north-eastern region has the highest age-
adjusted rate of 16.1 per 10,000 as of 2016 4. Connecticut is no exception to this trend – from 
2014-15 it was second only to New York state in percent-increase of deaths due to fentanyl, and 
deaths due to opioids generally grew by about 27% in that same period to 11.3 per 100,0005. 
Other than alcohol dependence, opioid dependence had the highest absolute Disability 
Adjusted Life Years (DALYs) of all other measured drug use disorders, accounting for 46% of 
all substance-abuse-related DALYs excluding alcohol. This is partially due to the fact that opioid 
dependence was given a higher disability weight (.64) than all other substance use disorders, and 
was considered to be closer to disorders such as severe epilepsy (.66), severe multiple sclerosis 
(.70), or acute schizophrenia (.76), suggesting severe disability associated with the disorder6. The 
Council for Economic Advisors estimated the total economic impact of the opioid epidemic in 
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2015, including premature death, incarceration, and other non-fatal costs, at $504 Billion7 - about 
2.8% of the national GDP. 
It is important to recognize that the majority of those with opioid use disorder are not in 
treatment. One study found that about 26% of patients with opioid use disorder had ever attended 
an alcohol or drug treatment program, while only 19% had attended an opioid-specific treatment 
program8. One analysis of treatment utilization nationally found that about 77% of US states 
reported that their opioid treatment programs were operating at 80% capacity or above, 
suggesting that lack of access to treatment and related service options might present a barrier to 
entry for many patients seeking help9. Additional evidence suggests that early entry to treatment 
might be beneficial for long term remittance of opioid use as duration of opioid use/dependence 
has been associated with increased likelihood of relapse to opioid use10. One survey found that 
more patients with substance use disorder were willing to enter treatment from their primary care 
provider than from a drug treatment program11, and this appears to be reflected in patient contact 
with healthcare providers – the majority of substance using patients encounter a primary care 
physician long before they begin specialized drug treatment12. 
Background  
As in many public health crises, primary care providers are serving as the front line 
against the opioid epidemic in the US13. Implementation of programs such as the Screening, 
Brief Intervention, and Referral to Treatment (SBIRT) for the identification and referral of 
opioid users in the primary setting is often discussed and promoted as one way in which these 
providers can better serve in this role, but implementation appears to be severely lagging behind 
the need for these services14. Many barriers to implementation have been identified, but another 
complimentary approach is to demonstrate and evaluate the utility of the screening tools used, 
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such as the Alcohol, Smoking, and Substance Involvement Screening Tool (ASSIST) for opioid 
use within the primary care setting. The ASSIST is one of several possible screening tools which 
can be used for an SBIRT program. 
 The ASSIST was developed in the early 2000s by the World Health Organization in order 
to serve as a screening tool for substance use (including tobacco and alcohol) internationally. It 
was designed to be applicable across international and cultural borders, capturing differing 
patterns of substance use across these boundaries, and has been translated into many languages. 
The screening tool was also intended to meet multiple objectives, such as case finding and risk 
factor screening. These features were found specifically limited in existing screening tools, and 
the development of the ASSIST was intended to address these concerns while improving 
sensitivity and specificity15. 
 The ASSIST underwent extensive testing and redevelopment over a period of several 
years, and is now in its third revision. Currently the ASSIST addresses 11 substance categories; 
tobacco, alcohol, marijuana, cocaine or crack, prescription stimulants, methamphetamine, 
inhalants, sedatives or sleeping pills, hallucinogenic/psychedelics, non-medical use of 
prescription pain medication, and heroin, as well as another option for substance not fitting into 
one of these categories. The ASSIST is administered by a provider and begins by asking about 
the lifetime use of each of these categories. For each substance the respondent reports use during 
their lifetime, seven follow-up questions are asked. Three of these questions pertain to the 
respondent’s lifetime use of this substance; the subject is asked if they have ever used any drug 
by injection, if a friend or relative has ever expressed concern about their use of the particular 
drug being asked about, and if the respondent has ever tried and failed to control their use of that 
drug. The remaining four questions pertain only to the past three months; they ask specifically 
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about the respondent’s frequency of use during this period, how often they have had a desire to 
use the substance, how often the use of that substance has led to problems in their life (health, 
social, legal, or financial problems), and how often they feel that they have failed to do what was 
expected of them because of their drug use. From the answers to these questions the provider 
may easily calculate a substance-specific score which indicates a risk category for that substance. 
These score categories indicate the risk of health and other problems related to the respondent’s 
use of that substance. In regards to its use within this SBIRT program, a ‘low’ score simply 
indicates feedback to the respondent, a moderate-low score indicates a brief intervention, a 
moderate-high score indicates a brief intervention as well as a brief treatment, and a high score 
indicates a brief intervention and referral to treatment16. 
 Following its initial development the ASSIST has been the subject of several validation 
studies. One study involving 1047 participants across multiple sites in seven countries examined 
the ASSIST for concurrent, construct and discriminative validity. In comparison with existing 
similar screening tools the ASSIST score had significant correlation. Furthermore these scores 
were associated with known substance abuse risk factors. Discriminative validity varied by 
substance and identification of use/abuse versus abuse/dependence (generally discriminative 
validity was higher in the case of use/abuse than dependence), but was generally found to be 
high with most AUC values above .75 and good values for sensitivity and specificity17. Other 
studies have found similar results18 19 20 21. 
 The SBIRT model is older and more studied than the ASSIST screening tool, but 
research regarding its efficacy remains incomplete. Several studies have examined the efficacy 
of the referral to treatment portion of the model with mixed results22 23. Most of these studies 
have focused on alcohol and comparatively few of them have used the ASSIST for screening 
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purposes. One study evaluated an implementation of SBIRT using the ASSIST and found that 
those who had received SBIRT had an increased utilization of outpatient services and a decrease 
of inpatient services, suggesting increased treatment utilization overall, but these results were not 
substance-specific and the ASSIST score itself was not included as a predictor for treatment 
utilization 24. Another study did not utilize the ASSIST but did examine efficacy for individual 
substance categories for a SBIRT project conducted in the ED setting – here it was found that 
those who went on to treatment may have had higher drug use severity scores generally, but 
there were insufficient heroin-using participants to establish this result more specifically for 
opioid users25. Currently no studies have evaluated the efficacy of an SBIRT program in the 
primary care setting for referral of opioid users to treatment, and no studies have evaluated the 
ASSIST opioid-specific score as a predictor of substance use treatment utilization. 
The aim of this analysis is to evaluate the utility of the ASSIST for use in a primary care 
setting in three major ways.  
 First we will investigate the validity of the ASSIST for identification of substance 
users by comparing patient responses to the ASSIST with matched clinical 
records. This will allow us to evaluate the accuracy of the information provided to 
the primary care provider when a patient does not indicate a history of opioid use 
(referred to as a  negative screen for opioids).  
 Second, we will determine the utility of the ASSIST substance-specific score as 
an indicator of prior treatment episodes. This will establish the relationship 
between substance use risk severity and treatment utilization. 
 Third, we will evaluate the efficacy of the ASSIST substance-specific score for 
prediction of future substance use treatment utilization within one year. If the 
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ASSIST score can be used effectively as a predictor of treatment, providers 
utilizing this tool could gain insight into their patients’ longer-term trajectory as 
well as their potential receptivity towards referral to treatment. 
Methods 
 This study utilized administrative and screening data sources to evaluate the ASSIST as 
an indicator of prior substance use treatment utilization, and as a predictor of future one-year 
entry to treatment for alcohol, opioid, and crack/cocaine users. Data was obtained from the 
Connecticut SBIRT administrative database . Patient SBIRT records were matched with 
administrative data from the Connecticut Department of Mental Health and Addiction Services 
(DMHAS) DDaP records system. Data were collected from screenings completed from 
01/01/2012 to 12/31/2015 including 31,744 records of 28,637 individual study subjects, 25,540 
of whom were sampled for this study, having been identified for positive lifetime use of alcohol, 
opioids, or crack/cocaine. Initial subjects were sampled from the population using random 
sampling, drawing on patients visiting a community health center within the study period who 
elected to participate in the study. ‘Positive lifetime use’ here indicates one of the following 
conditions were true for the study subject; 
1. The subject self-identified as having ever used non-medical use of heroin, prescription 
opioids, alcohol, cocaine, or crack at least once within their lifetime. 
2. The subject had a medical diagnosis indicating use of heroin, prescription opioids, 
alcohol, cocaine, or crack at least once within their lifetime. 
3. The subject had a clinical indicator, such as ‘drug of choice’, ‘primary drug’, ‘secondary 
drug’, or ‘tertiary drug’, indicating use of heroin, prescription opioids, alcohol, cocaine, 
or crack at least once within their lifetime. 
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 CT DMHAS was awarded a five-year grant from the federal Substance Abuse and 
Mental Health Services Administration (SAMHSA) in 2011 to establish the CT SBIRT program. 
The goals of this program were to introduce SBIRT services to provider settings such as 
community health centers, support brief interventions for substance and alcohol use, improve 
patient linkage to treatment programs, and to find ways to improve access to substance and 
alcohol use treatment. The University of Connecticut Health Center (UCHC) conducted a 
program evaluation to assess these goals and to monitor the implementation of the program. 
UCHC established the SBIRT training institute and trained ten full-time-equivalent health 
educators to serve ten community health centers in Connecticut. The role of these Health 
Educators was to understand and implement the SBIRT program in a community health center 
setting while collecting data for evaluation of the program. 
 Health educators (HEs) underwent training for a period between seven days to one month 
depending on prior experience. These educators were provided ongoing coaching and evaluation, 
and were eventually certified in SBIRT implementation. Health educators who completed their 
training were expected to understand the roles of all services provided by CT SBIRT and all 
available services as related to substance use. Educators were trained extensively in motivational 
interviewing practice and theory (part of the brief intervention protocol), as well as common 
conditions and challenges in health centers, and SBIRT protocols for screening, brief 
intervention, and referral to treatment. Additional training focused on establishing an 
understanding of patient confidentiality issues, HIPAA regulations, ethical requirements, and 
elements of cultural proficiency. HEs were expected to ensure that data relating to the 
Government Performance and Results Act (GPRA) were processed properly, and these educators 
were also informed of the requirements and importance of collecting this data. 
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 Health educators worked in ten Connecticut community health centers that participated in 
the CT SBIRT program. Community health centers often serve underserved and low-income 
people. These populations tend to be racially and ethnically diverse, and a relatively high 
proportion of their population are uninsured. The health centers which opted to participate in the 
SBIRT program were located across Connecticut. Table 1 shows labels for individual 
community health centers as well as the size of the sample drawn from that health center and 
percentage of the total sample. Some portions of Connecticut may have been over or under 
represented in this sample based on the distribution of the health center locations. 
The populations served by community health centers, especially those uninsured or 
Medicaid-eligible, may have an elevated risk of substance use disorder. The CT SBIRT program 
sought to utilize community health centers because of the opportunity to focus on these high-risk 
individuals, while also demonstrating the implementation of a screening and brief intervention 
program in a primary care setting. 
Community Health 
Center Label 
Patients with positive lifetime use of Opioids, 
Alcohol,        or Crack/Cocaine 
Percent of 
sample 
A 6657 26% 
B 4053 16% 
C 2691 11% 
D 2904 11% 
E 2288 9% 
F 1864 7% 
G 1624 6% 
H 1424 6% 
I 1091 4% 
J 942 4% 
TOTAL 25540  
Table 1-Participating Community Health Centers Sampled with Location 
 Screening and intervention procedures were established in these ten CHCs, to be 
primarily implemented by trained HE staff. All randomly selected patients presenting to the CHC 
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would be introduced to the HE as a member of the patient’s care team. The HE would establish 
rapport with the patient and would also record relevant demographic data. Using the ASSIST, the 
patient would be screened for alcohol and substance use, and the HE would calculate the 
patient’s substance-specific score. The ASSIST was chosen as the screening tool for this 
program because of its high discriminant validity, and its capacity to assess a wide range of 
substance categories. The ASSIST assesses the following substance categories; tobacco, alcohol, 
marijuana, cocaine or crack, prescription stimulants, methamphetamine, inhalants, sedatives or 
sleeping pills, hallucinogens or psychedelics, prescription pain medication (non-medical use), 
heroin, or other drugs. 
The version of the ASSIST utilized for this program asks the subject seven questions and 
may be found in Appendix A. Three of these questions pertain to the lifetime substance use of 
the subject; they ask if the subject has ever used the substance, if their friends or relatives have 
ever expressed concern about their use of the substance, and if they had ever tried and failed to 
cut down or stop using the substance. These questions allow the user to specify if these occurred 
within the past three months or not. The four remaining questions address the subject’s use of the 
substance within the past three months specifically, and allow the user to specify frequency 
(‘daily’, ‘weekly’, ‘monthly’, etc.). These questions ask the user about frequency of substance 
use, frequency of having a strong desire or urge to use the substance, how often the use of this 
substance has led to social, health related, or financial problems, and finally, how frequently use 
of the substance has led the user to fail to do what was normally expected of them. All of these 
questions are asked for each substance for which the user reports positive lifetime use. All of the 
responses to these questions have an associated weighted score, and the calculation of the 
substance-specific score is the summation of all of the weighted scores for each response 
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pertaining to that substance for the subject, with the exception of the question pertaining to 
lifetime ever-use. Under the rubric of the CT SBIRT program these scores are then categorized 
into one of four categories; ‘low’, ‘moderate-low’, ‘moderate-high’ or ‘high’ levels of risk for 
developing health and other problems related to current patterns of use. These cutoffs varied by 
substance. A score for alcohol below 11 points was considered ‘low’, between 11 and 19 was 
‘moderate-low’, 20-26 was considered moderate-high, and anything 27 or higher was considered 
‘high’. Drug categorizations for ‘moderate-high’ and ‘high’ score categories were the same, but a 
score below 4 was considered ‘low’ for drug use, with a score between 4 and 19 being 
‘moderate-low’. The ASSIST Lifetime score was not used by the HE within their assessment but 
was used for this study. The ASSIST Lifetime score is calculated by assigning 3 points for every 
substance category (including tobacco and alcohol) for which the respondent reports lifetime 
ever use. The ASSIST lifetime score can be viewed as an indicator of lifetime poly-substance 
use. 
 Once the HE obtained the substance-specific score for the subject, he/she proceeded with 
the SBIRT procedure according to the score category of the user. If the user scored in the ‘low’ 
category for any substance the HE explained the results and encouraged the subject to continue 
to pursue positive health choices. If the patient scored in the ‘moderate-low’ category the HE 
offered the patient the opportunity to receive a brief intervention relating to this substance use. If 
the patient accepted this offer, the HE would provide a brief 10-15 intervention using a 
counseling style called motivational interviewing. This brief intervention would involve 
coaching the subject through a review of strategies for change, and literature would also be 
provided relating to the effects of drugs and alcohol use. One possible limitation of this study is 
that subjects at different levels of motivation could have received different interventions, 
Adam Chess | Page 11 
 
depending on their willingness to receive these interventions. If the patient scored in the 
moderate-high category, or if they requested it, the subject would also receive a verbal 
recommendation for a brief treatment, or a referral to a substance use treatment provider. If the 
subject scored in the high-risk category for development of health and other problems related to 
current patterns of use, the HE provided feedback and referred the patient to a specialty 
substance use treatment provider. It is a recognized limitation of this study that those in the 
‘moderate-high’ and ‘high’ categories were likely to have been referred to substance use 
treatment, and that this complicates the evaluation of the relationship between ASSIST score and 
one-year entry to treatment. The results of this study are evaluated with this limitation in mind. 
 The data for this study consists of a sample of 25,540 patients screened via the CT 
SBIRT program who were positively identified via the ASSIST or other clinical measures for 
lifetime ever-use of alcohol, cocaine/crack, or heroin/prescription pain medication, screened 
between 01/01/2012 and 12/31/2015. The initial screened population included all adults ages 18 
and older who presented at one of the ten health centers within these dates. Through use of the 
LinkKing software package these records were matched to the CT DMHAS DDaP database. 
Linking these records allowed clinical information, including administrative records of treatment 
utilization, to be linked to responses on the ASSIST. Records were linked on the basis of patient 
names, date of birth, and social security number when available. None of this personally 
identifiable information was contained in the final dataset. This DMHAS database included 
demographic information as well as diagnostic records, clinical measures, and substance abuse 
treatment utilization records for anyone admitted to a licensed substance use treatment facility in 
Connecticut. Specifically, this database included admission and discharge dates and records for 
all Connecticut mental health and substance use treatment patients, including inpatient, 
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outpatient, and methadone treatment programs. All screening response data was contained in the 
CT SBIRT database which itself also included demographic data and records of treatments and 
services provided. 
Statistical Analyses 
A number of statistical modeling methods were used for this study. All reported p values 
throughout the study have been adjusted for multiple comparisons by the Benjamini and 
Hochberg False Discovery Rate controlling procedure, and all power analyses were conducted 
by post-hoc Monte-Carlo simulation. Throughout this study, all logistic and Poisson regression 
models were evaluated for multicollinearity using VIF analysis. Few VIF statistics were found to 
be below 2.5, indicating low to moderate multicollinearity, but in cases where VIF statistics were 
higher than 2.5 one of the collinear variables was removed from the model. All adjusted pseudo-
R2 values were calculated as McFadden’s adjusted R2 statistics. 
Analyses focused on three distinct aims; 
1. Describing the characteristics of the sample, including the capacity of the ASSIST to 
identify substance users, as well as related sample characteristics. 
2. Assessing the relationship between the ASSIST substance-specific score and prior 
substance use treatment utilization. 
3. Assessing the capacity of the ASSIST substance-specific score to serve as a predictor of 
future treatment utilization within one year. 
Aim 1: 
Characterization of the sample involved assessing the differences between subjects who were 
identified as substance users by the ASSIST versus those who were identified by another 
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method. Odds Ratios were calculated comparing the odds of entry to substance use treatment 
within  one year for those identified on the ASSIST versus those who were not identified in this 
way. All ORs were calculated using logistic regression. These estimates were adjusted for 
ASSIST substance-specific score, age, gender, race, ethnicity, number of prior substance use 
treatment episodes, number of prior mental health treatment episodes,  and number of positive 
ever-use substance categories on the ASSIST. Further comparisons between substance users by 
the ASSIST versus those who were identified by another methods were completed using t tests 
and chi-squared tests, where appropriate.  
This section of the study also involved a targeted analysis of the sample indicating opioid 
use, specifically assessing non-medical prescription opioid use versus heroin use. Comparisons 
of each three groups (prescription opioid users, heroin users, and users of both) were completed 
using t-tests and chi-square tests; each category being compared to a combination of the other 
two. Logistic regression models were found to compare the odds of entry to treatment within one 
year from each group against the remaining two groups. These logistic regression models 
adjusted for the log of the number of prior substance use treatment episodes, whether or not the 
subject was identified via the ASSIST, the log of the ASSIST Lifetime use score, age, gender, 
race, ethnicity, and the log of the number of prior mental health treatments. The results of these 
analyses were odds ratios for each of the three categories with 95% confidence intervals. 
Additionally a time trend analysis was conducted using a linear regression model. 
Aim 2: 
 Assessing the relationship between the ASSIST substance-specific score involved several 
statistical models. Characteristic comparisons between substance users with and without a 
recorded prior substance use treatment episode were done by t tests and chi-square tests, as 
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appropriate. Rate ratios, indicating the relative increase in prior treatment utilization incidence 
for every 10 points on the ASSIST substance-specific score, were calculated by multivariable 
Poisson regression models. These models were adjusted for the subjects ASSIST identification 
status, the log of the ASSIST Lifetime use score, age, gender, race, ethnicity, the log of the 
number of prior mental health treatments, and in the case of Opioids, the specific category of 
Opioid use reported (prescription opioid users, heroin users, and users of both). These Poisson 
models were adjusted for overdispersion using the method described by Breslow (1984)26. 
Aim 3: 
 The evaluation ASSIST substance-specific score as a predictor of entry to substance use 
treatment within one year also involved several statistical models. Unadjusted odds ratios 
comparing the ASSIST scores of those who did go on to treatment to those who did not utilized 
logistic regression, while the adjusted odds ratios were calculated from multivariate logistic 
regression. These later models adjusted the Odds ratio by the log of the number of prior 
treatments, whether or not the subject was identified via the ASSIST, the log of the ASSIST 
Lifetime use score, age, gender, race, ethnicity, the log of the number of prior mental health 
treatments, and in the case of Opioids, the specific category of Opioid use reported. Comparisons 
of these characteristics between those who went on to treatment within one year versus those 
who did not were conducted via chi-square and t-tests as appropriate. 
 Comparison between different risk categories of odds of entry to treatment within one 
year were developed in a similar way using multivariable logistic regression, adjusting for the 
same variables. For these analyses the comparison category was always the ‘low’ risk category. 
Comparisons of risk categories by percent going on to treatment within one year were conducted 
using chi-square analysis. 
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 A target reshuffling technique was used to assess variable importance in the multivariable 
logistic regression modeling ASSIST score and one-year entry to treatment among opioid users. 
The multivariable logistic regression was bootstrapped while systematically reshuffling each 
variable in the model in order to determine the degree to which re-shuffling of this variable 
reduced the final adjusted pseudo-R2 values; this allows an approximation of the degree to which 
each variable contributed to the final model-fit, and thus an approximation of its utility for 
prediction of one-year entry to treatment.  
 Finally, several findings from this section of the study were identified, and E-Values 
were calculated for these results along with lower 95% confidence intervals, in order to 
contextualize the possibility of potential unaccounted confounding effects. These values were 
calculated using the methods described in by VanderWeele and Ding27. 
 
RESULTS 
 Sample Characteristics, validity of the ASSIST for identification of substance users, and 
related sample characteristics 
  
ID 
Method     
Substance   ASSIST Drug Type Diagnosis TOTAL 
Opioid n 2067 893 903 2427 
 % 85% 37% 37%  
Alcohol n 17999 1178 1066 18266 
 % 99% 6% 6%  
Crack/Cocaine n 4541 979 847 4847 
 % 94% 20% 17%  
Table 2-Identification methods for three substance categories 
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Of 28,637 patient records 2,427 were identified as having ever used non-medical opioid 
or heroin. 18,266 alcohol users were identified as well as 4,847 users of cocaine or crack. 
Patients were identified by three possible means – by any positive indication on the ASSIST for 
that substance, by a clinical diagnosis in the DMHAS treatment record indicating use of that 
substance, or by an appearance of that substance on the patient’s primary, secondary, or tertiary 
reported drug type indicator. Table 2 shows the number and percentage of patients identified via 
each method. Throughout this study ‘Post treatment’ refers to a record of a substance use 
treatment episode which occurred within one year from the ASSIST screening date.  
 Of note are those patients who did not have a positive indication on the ASSIST while 
having a positive indication via drug type or diagnosis. For alcohol and cocaine/crack this group 
was only 1% and 6% of the total number of users, respectively, but for opioids 15% of those 
identified failed to indicate lifetime use on the ASSIST while having a positive diagnosis or drug 
type indicator. Figure 1 shows three Euler diagrams illustrating the proportionality of these 
identification methods for each substance category, illustrating generally stronger crossover  
Figure 1-Visual representation of identification method for three substance categories 
Adam Chess | Page 17 
 
between diagnosis and clinically indicated drug type than for positive ASSIST identification with 
either of these two others. These results suggest that respondents are more likely to admit to 
alcohol or cocaine use than opioids when screened via the ASSIST. 
 Patients who were positively identified via clinical measures (Drug type or diagnosis), 
but were unidentified via the ASSIST will be referred to here as non-ASSIST patients. These 
patients showed different 
characteristics than those 
who were identified via 
the ASSIST. These 
differences are shown in 
Table 3 with p-values 
adjusted for confounding 
and multiple comparisons 
by the Benjamini and 
Hochberg False 
Discovery Rate 
controlling procedure.  
Among opioid, 
alcohol, and 
crack/cocaine users there 
were significant differences in the odds of entry to treatment within 1 year, with those who failed 
to be identified on the ASSIST consistently showing higher odds of entry to treatment after 
Opioids 
ASSIST-
ID 
No-
ASSIST p(adj) Power 
1 year post Treatment adjusted 
OR 0.19 5.19 
0.000 100% 
Mean # of prior SA treatments 5.35 9.52 0.000 100% 
Mean Age 44.28 41.6 0.000 100% 
Percent Male 63.50% 58.60% 0.794 5% 
Percent Hispanic 34.30% 28.90% 0.026 70% 
Percent White 56.17% 56.39% 0.794 6% 
Alcohol 
ASSIST-
ID 
No-
ASSIST p(adj) Power 
1 year post Treatment adjusted 
OR 
0.06 
15.47 
0.000 100% 
Mean # of prior SA treatments 1.11 9.43 0.000 100% 
Mean Age 43.99 43.06 0.462 11% 
Percent Male 41.77% 61.50% 0.000 100% 
Percent Hispanic 46.14% 18.72% 0.000 100% 
Percent White 41.17% 49.44% 0.243 23% 
Crack/Cocaine 
ASSIST-
ID 
No-
ASSIST p(adj) Power 
1 year post Treatment adjusted 
OR 0.13 7.66 
0.000 100% 
Mean # of prior SA treatments 3.62 9.41 0.000 100% 
Mean Age 46.54 41.65 0.000 100% 
Percent Male 58.56% 59.15% 0.651 8% 
Percent Hispanic 34.05% 31.70% 0.367 20% 
Percent White 49.33% 49.35% 0.704 9% 
Table 3-Characteristics of ASSIST-identified and ASSIST non-identified subjects by 
substance category 
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controlling for potential confounding factors such as number of prior treatments, ASSIST 
substance-specific score, ASSIST lifetime substance use score, and other demographic factors.  
 Among opioid users there were also differences between users of prescription opioids, 
heroin users, and those who used both substance categories. Figure 2 shows the percentage of all 
opioid users who fell into the prescription opioid, heroin, or heroin and prescription opioid 
categories for each month of the study period, along with a trend line and standard error. A weak 
trend was detected for the proportion of prescription opioid users per month, but this was not 
statistically significant (p=.639). A moderate downward trend was detected for the proportion of 
heroin-only users (p=.001), and a moderate upward trend was detected for the proportion of both 
prescription opioids and heroin users (p=.009). These results suggest that while heroin-only users 
typically made up a greater proportion of all opioid users, over the course of the study period 
more of these heroin users also reported use of prescription opioids. While these trends may 
represent national or regional historical changes, sampling bias cannot be ruled out as an 
explanation. 
Figure 2-Trends in Opioid use over 35 month study period 
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 Table 4 shows additional differences between these categories of Opioid use. Mean 
ASSIST substance-specific scores were found by excluding all opioid users who had substance-
specific scores of zero, excluding all users not identified by the ASSIST. For mean prior 
substance use treatment records, values for each category were compared to other categories 
independently, and all categories were found to be significantly different with all p values below 
.0001. For a mean ASSIST score, however, prescription-only user scores were not found to be 
significantly different from heroin-only user scores. For calculation of adjusted post-treatment 
odds ratios, the comparison group was in each case the other two categories (see note 27). 
 
 Additional characteristics were found to be different among these three categories, as 
shown in Table 5. Here characteristics for each opioid type were statistically compared 
individually against each other opioid type. For example, the sample of prescription-opioid-only 
users (‘A’) which was  55.9% male, was found to be significantly different than the sample of 
Opioid Type n 
% 
total 
Mean ASSIST 
Score (+ID Only, 0 
Scores Excluded) 
Mean Prior SU 
treatment 
records 
Post Screening 
Treatment aOR with 
95%CI 
A) Rx Only 399 16.44% 6.12 1.89 .21 (.13 -- .32) 
B) Heroin Only 1276 52.57% 7.22 6.44 .8 (.64 – 1.01) 
C) Rx & Heroin 752 30.98% 9.13 7.34 2.33 (1.86—2.92) 
Table 4-ASSIST Scores, Prior treatments, and Odds Ratio of Post Treatment for three categories of Opioid use 
Opioid type 
Mean 
age 
% 
Male 
% 
White 
% 
Hispanic 
% non 
ASSIST 
ID 
Mean prior 
MH 
Treatment 
records 
ASSIST 
Lifetime 
Score28 
A) RX Only 37.9 55.9% 59.2% 32.6% 3.3% 1.73 5.98 
B) Heroin Only 47.6 65.6% 47.7% 40.0% 17.9% 2.69 4.74 
C) RX & Heroin 40.8 61.7% 69.2% 22.9% 15.8% 2.64 4.40 
p < .05 
[AvB,BvC,AvC] 
Y,Y,Y Y,N,N Y,Y,Y Y,Y,Y Y,N,Y N,N,N Y,N,Y 
Table 5-Characteristic Differences between three opioid use categories 
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heroin-only users (‘B’) which was 65.6% male, but it was not found to be significantly different 
than the sample of prescription-and-heroin users (‘C’), which was 61.7% male. Nor was ‘B’ 
significantly different from ‘C’ at the p < .05 level. Thus in Table 5 under ‘% Male’ we see 
‘Y/N/N’ indicating that the ‘A’ versus ‘B’ comparison was statistically significant, but the the 
‘B’ versus ‘C’ and the ‘A’ versus ‘C’ comparisons were not. These differences in statistical 
significance suggest a complex relationship between opioid type and several of these 
characteristics. For instance, no statistically significant difference was found between the 
percentage of users which failed to be identified by the ASSIST among the heroin-only and the 
prescription-and-heroin users, but both of these groups were found to have a statistically 
significant higher percentage than the prescription-only group. This suggests that heroin use 
affects the ability of the ASSIST to identify opioid users more than prescription opioid use. 
Other important characteristic differences include age, where prescription opioid users were 
found to be younger than heroin and prescription-and-heroin users, and heroin-only users were 
found to be older than the other two categories. Statistically significant racial and ethnic 
differences were also observed, with heroin-only users most likely to identify as Hispanic and 
least likely to identify as white, while prescription-and-heroin users were least likely to identify 
as Hispanic and most likely to identify as white. No statistically significant differences were 
found among the number of recorded prior mental health treatments. It was found that 
prescription-only opioid users reported lifetime ever-use of more substance categories than 
heroin-only or prescription-and-heroin users. 
Assessing the relationship between the ASSIST substance-specific score and prior 
substance use treatment utilization. 
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 For opioids, alcohol, and cocaine/crack, differences in characteristics were also found 
between those who had prior substance use treatment, those who did not, and those who were 
within the highest decile number of prior treatment use. Table 6 shows some of these 
characteristic differences, and also shows the mean ASSIST substance-specific score for each 
group. All sample size values in this table exclude subjects who failed to be identified via the 
ASSIST. Mean ASSIST scores are presented excluding scores of 0 (indicating that they were not 
identified by the ASSIST), and also including these scores. The mean ASSIST scores excluding 
the 0 scores represent the ASSIST scores of those who did and did not have prior substance use 
treatment episodes. The mean ASSIST scores including all 0 scores represent what would 
actually be observed from the perspective of the provider without knowledge of who the ASSIST 
failed to identify. 
While many of these characteristics appeared significantly different in the case of alcohol 
and cocaine/crack, only the mean ASSIST substance-specific score was found to be a statistically 
significant indicator of prior substance use treatment for opioids. More generally, those who had 
prior treatments in all categories were usually more likely to be male, younger, and white, while 
they were usually less likely to be Hispanic. For alcohol and cocaine/crack  
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characteristic trends appeared largely consistent for those without prior treatments, those with  
Opioids  Prior Substance Use Treatments   
N= 1230 None 1 or More Adjusted p 
value   (None vs 
1+) 
  90th 
Percentile 
(17+) n=139 
Adjusted 
p value   
(None vs 
90th%) 
  
Comparison n=309 n=921 Power Power 
Mean ASSIST 
Score 
(Scores>0) 
6.8 8.13 .006 74% 9.29 .004 89% 
Mean ASSIST 
Score (All) 
2.9 4.41 <.001 100% 5.1 <.001 100% 
Mean Age 44.72 43.52 0.055 62% 43.42 0.164 29% 
Percent Male 59.30% 64.30% 0.055 62% 65.60% 0.453 39% 
Percent Hispanic 36.10% 32.40% 0.1 42% 22.90% 0.001 97% 
Percent White 53.80% 57.20% 0.137 32% 57.70% 0.658 17% 
Alcohol  Prior Substance Use Treatments   
N= 17999 None 1 or More Adjusted p 
value   (None vs 
1+) 
  90th 
Percentile 
(3+) n= 1843 
Adjusted 
p value   
(None vs 
90th%) 
  
Comparison n= 14349 n= 3650 Power Power 
Mean ASSIST  
Score 
(Scores>0) 
1.84 4.17 <.001 100% 4.85 <.001 100% 
Mean ASSIST 
Score (All) 
1.83 3.9 <.001 100% 4.38 <.001 100% 
Mean Age 44.26 42.93 <.001 100% 43.92 0.21 16% 
Percent Male 36.90% 61.00% <.001 100% 63.50% <.001 100% 
Percent Hispanic 49.80% 30.70% <.001 100% 25.50% <.001 100% 
Percent White 39.60% 47.50% <.001 100% 49.50% <.001 100% 
Cocaine/Crack  Prior Substance Use Treatments   
N= 4541 None 1 or More Adjusted p 
value   (None vs 
1+) 
  90th 
Percentile 
(12+) n= 439 
Adjusted 
p value   
(None vs 
90th%) 
  
Comparison n=2224 n=2317 Power Power 
Mean ASSIST  
Score 
(Scores>0) 
2.37 4.18 <.001 100% 5.62 <.001 100% 
Mean ASSIST 
Score (All) 
2.35 3.72 <.001 100% 4.76 <.001 100% 
Mean Age 47.78 44.9 <.001 100% 43.66 <.001 100% 
Percent Male 55.20% 61.40% <.001 99% 62.20% 0.086 81% 
Percent Hispanic 39.40% 29.10% <.001 100% 22.60% <.001 100% 
Percent White 48.60% 50.00% 0.358 15% 54.80% 0.012 71% 
Table 6-Characteristics of subjects by number of prior substance use treatment episodes 
Adam Chess | Page 23 
 
one or more prior treatments, and those with a number of prior treatments in the top decile.  
 Alcohol users with a number of prior treatments in the top decile, for instance, were 
more likely to be male than those with any number of prior treatments, who were much more 
likely to be male than those with no prior treatments. These trends were also largely consistent 
among opioid users, but most of these differences were not statistically significant. For each 
substance category, the ASSIST substance-specific score was found to be different for each of 
these groups, generally increasing with the number of prior treatments, and these differences 
were highly statistically significant.  
 In order to establish the efficacy of the ASSIST substance-specific score for imputing the 
number of prior treatments, a Poisson regression was performed for each of the substance 
categories. Table 7 shows the results of these Poisson regressions in the form of the adjusted rate 
ratio for every increase of 10 points on the ASSIST substance-specific score. These values 
represent the relative incidence rate of prior treatment for every 10 point increase in the ASSIST 
substance-specific score. For example, for every increase of 10 points on the ASSIST substance-
specific score for opioids, the incidence rate of prior treatment increases by 23% (95% 
confidence interval: 13% to 33%), and including adjustment for possible confounding variables, 
this model accounts for about 21% of the total variance in prior treatment incidence. Looking 
back to table 7, we see that these results indicate that holding the substance-specific score 
constant, and adjusting for a number of covariates, cocaine/crack users have a higher relative rate 
of substance use treatment than alcohol or opioid users, and that opioids had the lowest relative 
Substance Category Adj Rate Ratio per 10 score 95% CI p value Adjusted Psuedo-R2 
Opioids 1.23 (1.13-1.33) <.001 0.21 
Alcohol 1.79 (1.57-1.99) <.001 0.24 
Cocaine/Crack 1.88 (1.75-2.01) <.001 0.16 
Table 7-Adjusted Rate Ratios per increase of 10 substance-specific ASSIST score by substance category 
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rate of prior substance use treatment. This follows from the fact that adjusted rate ratios for 
cocaine/crack were found to be higher than alcohol and opioids, and that opioids had the lowest 
rate-ratios of the three.  
Assessing the capacity of the ASSIST substance-specific score to serve as a predictor of 
future treatment utilization within one year. 
 For each of the three substance categories evaluated, there were significant differences 
between subjects who entered treatment within one year and those who did not. Table 8 shows 
these differences with associated p values adjusted for all other variables as well as multiple 
comparisons. For mean ASSIST substance-specific score comparisons, only those who  
 were identified via the ASSIST were included. While there are a number of significant 
differences identified between those who did and did not go on to treatment within one year, a  
Table 8-Characteristics of subjects who did and did not go on to treatment within one-year by substance category 
 Opioids   Alcohol   Crack/Cocaine   
 
Post 
Treatment 
No Post 
Treatment p(adj) Power 
Post 
Treatment 
No Post 
Treatment p(adj) Power Post Tx 
No 
Post Tx P (adj) Power 
 n=650 n=1777   n=966 n=17300   n=794 n=4053   
Mean ASSIST Score 
(+ASSIST ID only) 
7.52 3.88 <.001 100% 5.48 2.16 <.001 100% 5.27 2.99 <.001 100% 
Mean Age 40.87 44.98 <.001 100% 40.99 44.14 <.001 100% 41.81 47.10 <.001 100% 
% ASSIST-ID 66.77% 91.90% <.001 100% 85.40% 99.27% <.001 100% 77.96% 96.77% <.001 100% 
% Male 66.31% 61.51% 0.004 86% 64.70% 40.76% <.001 100% 64.99% 57.29% <.001 99% 
% White 59.08% 55.15% 0.624 10% 51.44% 40.72% 0.175 28% 53.27% 48.56% 0.872 5% 
% Hispanic 30.46% 34.61% 0.681 7% 27.64% 46.75% <.001 100% 27.96% 35.06% 0.007 78% 
ASSIST Lifetime 
Score 
5.39 5.91 0.140 37% 4.64 2.57 <.001 100% 5.22 4.80 0.044 56% 
# Prior MH treatments 2.93 2.37 0.681 8% 2.71 0.82 0.577 10% 3.12 2.02 0.879 6% 
# Prior SU treatments 10.39 4.35 <.001 100% 8.84 0.81 <.001 100% 10.13 2.78 <.001 100% 
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few are of particular note. Mean ASSIST substance-specific scores were significantly higher for 
those who had a post-ASSIST treatment admission than for those who did not, but this difference 
was greatest for opioid users. Very similar age differences for treatment versus no-treatment 
were found across each substance category, though crack/cocaine users tended to be older. The 
ASSIST lifetime score only attained significance for alcohol users. Interpreting the ASSIST 
Lifetime score as a surrogate measure for poly-substance use, this result suggests that some of 
the treatment episodes for this category may have been for substances other than alcohol. The 
number of prior treatments differed among those who did and did not go on to treatment, but the 
differences in prior mental health treatments was smaller and not statistically significant, while 
the differences in prior substance use treatments were larger and highly statistically significant.  
Substance 
Unadjusted 
OR/10 
29Unadjusted 
psuedo-R2 
30aOR/10 
aOR 
95%CI 
Adjusted psuedo-
R2 (r) 
Opioids 1.30 0.01 1.38 1.23 - 1.54 0.21 (r=.45) 
Alcohol 1.98 0.03 1.53 1.39 - 1.66 0.35 (r=.59) 
Cocaine 1.52 0.01 1.43 1.25 - 1.60 0.24 (=.49) 
Table 9-Odds Ratios of one-year entry to treatment for every 10 points on the ASSIST substance-specific score 
Figure 3-Adjusted Odds-ratios for each ASSIST score category compared to the ‘Low’ category where outcome is entry into 
treatment within one year 
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 In order to determine the utility of the ASSIST substance-specific score as a predictor of 
entry to treatment within one year, a multivariate logistic regression was run. Results for this 
analysis are shown in table 9, where Odds ratios of entry to treatment are shown for every  
increase of 10 points on the ASSIST substance-specific score. Additional analyses were 
conducted examining the ASSIST substance-specific score categories (High, Moderate-High, 
Moderate-Low, and 
Low) as predictors of 
one-year entry to 
treatment. Figure 3 
shows the adjusted 
odds ratios with 95% 
confidence intervals 
of each score 
category for subjects 
who scored in the 
‘Low’ category. With 
the exception of the 
‘Moderate-Low’ 
category for opioids, 
odds ratios appear 
elevated over ‘Low’ 
for every category, 
but differentiation 
Opioids     
Comparison 
%Post 
First 
Category 
%Post 
Second 
Category 
Adjusted p Power 
Mod-High vs High 45.45% 49.32% 0.831 7% 
Mod-High vs Mod-
Low 
45.45% 25.21% 0.010 100% 
Mod-High vs Low 45.45% 25.94% 0.010 100% 
High vs Mod-Low 49.32% 25.21% <.001 100% 
High vs Low 49.32% 25.94% <.001 100% 
Mod-Low vs Low 25.21% 25.94% 0.831 6% 
Alcohol     
Comparison 
%Post 
First 
Category 
%Post 
Second 
Category 
Adjusted p Power 
Mod-High vs High 26.58% 26.58% 0.878 5% 
Mod-High vs Mod-
Low 
26.58% 14.15% 0.001 84% 
Mod-High vs Low 26.58% 4.79% <.001 100% 
High vs Mod-Low 27.50% 14.15% 0.006 84% 
High vs Low 27.50% 4.79% <.001 100% 
Mod-Low vs Low 14.15% 4.79% <.001 100% 
Cocaine/Crack     
Comparison 
%Post 
First 
Category 
%Post 
Second 
Category 
Adjusted p Power 
Mod-High vs High 37.21% 43.75% 0.848 10% 
Mod-High vs Mod-
Low 
37.21% 40.24% 0.848 6% 
Mod-High vs Low 37.21% 15.49% 0.001 100% 
High vs Mod-Low 43.75% 40.24% 0.848 7% 
High vs Low 43.75% 15.49% <.001 100% 
Mod-Low vs Low 40.24% 15.49% <.001 100% 
Table 10-Multiple Comparisons of unadjusted percentage entering treatment within one year 
for three substance categories 
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between these categories appears poor. As the pseudo-R2 values in Table 8 show, the unadjusted 
models involving only the ASSIST substance-specific score as a predictor of one-year entry to 
treatment accounted for a very small percentage of total variance, while the models incorporating 
other factors in addition to ASSIST score (see note 30) accounted for much more of this 
variance. Table 10 shows the unadjusted percentages of one-year entry to treatment for each 
category comparison, with p values adjusted for multiple comparisons, for each substance 
category evaluated. Here differentiation between substance-specific score categories appears 
good.   
 In order to assess relative variable importance within the logistic regression model, a 
post-hoc target reshuffling method was utilized. The results of this process for opioids are shown 
in Figure 4. These results suggest that the most predictive factors among those evaluated in the 
model were the number of prior substance use treatments (‘log priors’), followed by the 
ASSIST–ID status of the subject, what kind of opioid they used (prescription opioids, heroin, or 
both), followed by the age of the subject, followed by the ASSIST substance-specific score. 
Figure 4-Approximations of variable importance for prediction of one-year entry to treatment among opioid users 
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Factors such as gender, race, ethnicity, the ASSIST Lifetime score, and the number of mental 
health prior treatments, all showed very small predictive value. The value on the y-axis of each 
bar corresponds to the estimated loss on the psueduo-R2 metric of the whole model by removal 
of that variable. For example, removing the ‘ASSIST_ID_Status’ variable, which represents 
whether or not the subject was identified via the ASSIST, reduced the psueduo-R2 metric of the 
model from .21 to about .19. 
Discussion 
 The results of this study indicate that the ASSIST is effective for predicting one-year 
entry to treatment and for estimating prior treatment utilization for users of prescription opioids, 
alcohol, and cocaine/crack in this multi-year state-wide sample. 
 Not all of those in the study could be identified as users of opioids, alcohol, or 
cocaine/crack via the ASSIST, and many subjects were rather identified by clinical indicators 
such as diagnosis. Proportionally, this appeared to be a much stronger effect among opioid users 
than alcohol or cocaine/crack users (85% identified versus 99% and 94%), however the true 
proportions may be lower than these estimates, as not all subjects had associated clinical 
information. Nevertheless, differences were observed between those who were and were not 
identified via the ASSIST. Entry to treatment within one year appeared strongly associated with 
failure to be identified on the ASSIST for all substance categories evaluated, even after adjusting 
for prior substance use treatment utilization, ASSIST score, and other variables. The reason for 
this difference is unclear, though there are a number of possible explanations. Those who deny 
their substance use on the ASSIST may have a more severe substance use disorder. It is also 
possible that this is a reflection of the implementation of the ASSIST in the primary care setting. 
This result may also be a result of the brief intervention portion of the SBIRT program, which 
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may have reduced the need for substance use treatment for those who scored within the 
Moderate-Low to Moderate-High range on the ASSIST substance-specific score. None of these 
explanations individually appear to completely explain the stark difference in adjusted odds 
ratios shown in Table 2, but some combination of them may do so. An additional question 
concerns the reason for this failure of identification on the ASSIST, especially among opioid 
users where about 15% failed to be identified. One possible explanation is the so-called 
phenomenon of ‘doctor shopping’ whereby non-medical prescription opioid users deny use 
status in order to obtain prescriptions for opioid from providers. The results from Table 4 suggest 
that this is not the case for this sample. Here subjects who only used prescription opioids were 
significantly more likely to be identified via the ASSIST than those who used heroin only or both 
heroin and prescription opioids. It appears that those opioid users who failed to be identified on 
the ASSIST were more likely to use heroin, were less likely to be Hispanic, had higher prior 
substance use treatment utilization, and were younger than those who were identified on the 
ASSIST. 
 There may be alternative explanations for these results. Subjects may have failed to 
identify lifetime use of a substance if they were presently using a medication intended to treat 
their substance use disorder, such as methadone. Alternatively, this result could be a reflection of 
the subjects’ readiness for change or motivation. It is possible that subjects seeking to deny 
substance use involvement are in fact more likely to have higher treatment utilization. More 
research is required to address this topic. 
 Several trends were identified in the analysis of opioid use by opioid type. Most of the 
subjects in the study used only heroin but the proportion of heroin-only users appeared to shrink 
over the course of the study, while the proportion of heroin-and-prescription opioid users grew at 
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approximately the same rate. The reason for this shift is unclear, but it appears to reflect ongoing 
historical trends during this time indicating greater proportions of heroin user reporting 
prescription opioid use prior to heroin use.31 
 Use of both prescription opioids and heroin appeared to be significantly associated with 
higher treatment utilization, both in terms of number of prior treatments and odds of entry to 
treatment within one year. Given the significant age differences within the three categories, 
along with the growing proportion of subjects reporting both heroin and prescription opioids 
over the course of the study period, it appears possible that this is representative of a ‘graduation’ 
effect, and a possible difference from the cohort of heroin-only subjects. On this interpretation 
the sample appears to show prescription opioid users as younger, more equally male and female, 
mostly white, with lower use disorder severity (indicated by significantly lower ASSIST scores), 
more poly-substance use (indicated by the significantly higher ASSIST Lifetime score), low 
prior substance use treatment utilization, and low probability of entry to treatment within one 
year. Under this ‘graduation’ view, some users of prescription opioids may go on to also use 
heroin. In particular these users are associated with higher substance use disorder severity and 
markedly greater treatment utilization, as well as a greatly increased odds ratio of entry to 
treatment within one year. Those who ‘graduate’ on to heroin are more likely to be white and 
male, and are less likely to be Hispanic. These users are also significantly more likely to fail to 
be identified on the ASSIST than those who use only prescription opioids. 
 Several of these results indicate that the ‘graduation’ hypothesis may fail to explain these 
results. Those who use both prescription opioids and heroin have significantly lower lifetime 
poly-substance use scores as indicated by the ASSIST Lifetime score. While this may be 
reconciled with a ‘graduation’ effect by taking into consideration the significantly higher 
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percentage failing to be identified on the ASSIST, it is more difficult to reconcile with the trends 
identified over the study period. These trends indicated fewer heroin-only users over the course 
of the study period, as well as an increased percentage of subjects reporting both prescription 
opioids and heroin, but the proportion of prescription opioid only subjects did not appear to 
fluctuate. Under the hypothesis that prescription-only users were ‘graduating’ to heroin use, we 
would expect to see a reduction in prescription-only subjects over the course of the study, given 
an increase in users of both prescription opioids and heroin. These results suggest that the so-
called ‘graduation’ hypothesis is unlikely to be the sole explanation for the differences between 
opioid users who use prescription opioids, heroin, or both. 
 Results assessing prior treatment utilization for different substance categories suggest that 
the ASSIST score is effective as an indicator of prior treatment utilization. Despite failure to 
achieve statistical significance and/or inability to obtain sufficient power for the given sample 
sizes across all comparisons, several trends in prior treatment utilization appeared within the 
sample. Treatment utilizers generally appeared to be younger, and were more likely to be male, 
white, and non-Hispanic. In regards to age specifically, statistical significance at the 90% 
utilization level was only achieved for crack/cocaine users. This result might reflect a trend 
towards cocaine/crack users entering treatment at an earlier age, or it could alternatively 
represent an increased frequency of treatment utilization within a similar period of time. 
While it may have been due to a smaller sample size, demographic differences between 
opioid users who did and did not utilize substance use treatment prior to ASSIST screening were 
not statistically significant, nor were demographic comparisons between those who did not 
utilize treatment and those who were in the top decile of substance use treatment utilization. This 
did not appear to be the case for alcohol and cocaine/crack users, where demographic differences 
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were detected. Overall, the ASSIST substance-specific score did significantly correlate with 
increased prior treatment utilization for all three substance categories and the sensitivity of this 
association did appear moderately strong. This was especially the case for cocaine/crack users, 
for whom an increase of 10 points on the substance-specific score indicated an 88% higher 
incidence of substance use treatment utilization. Effects were similarly strong for alcohol users 
who had a comparable 79% increase, but the effect was smaller for opioid users, who only had a 
23% higher incidence of treatment utilization for the same increase in ASSIST score. The R2 
values for each of these models indicate that while the ASSIST score may be more-or-less 
sensitive in association with prior treatment utilization, this score along with demographic 
variables included in the model account for only a small percentage of the total variance in 
treatment utilization. This was particularly the case for cocaine/crack, where the adjusted model 
accounted for 16% of the total variance, but the majority of the variance was also left 
unexplained for the alcohol and opioid models. ASSIST scores across all levels of prior 
treatment utilization appeared low, especially after inclusion of subjects who failed to be 
identified on the ASSIST. Therefore, while the association between ASSIST score and prior 
treatment utilization itself appears robust, sensitivity would likely have to improve before it 
could be effective for this purpose in a primary care environment. 
  Unsurprisingly, trends in various characteristic differences between those who did and 
did not go on to enter treatment within one year were similar to trends in prior treatment 
utilization. All tests for significance of these differences were calculated by controlling for other 
variables, including prior treatment utilization. Once again the size of the sample was not always 
sufficient to identify a statistically significant difference at the effect sizes observed, but trends 
appeared to hold across different substance categories regardless of this lack of statistical power. 
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Those who went on to a post-screening treatment within one year had higher ASSIST scores, 
were younger, were less likely to have been identified by the ASSIST, and were more likely to 
be male, and non-Hispanic. ASSIST Lifetime substance use scores tended to be higher among 
those who went on to treatment within one year, suggesting higher rates of poly-substance use, 
though this effect was not significant among opioid users. This difference was greatest among 
alcohol users, which is not surprising given that the entry to substance use treatment need not 
have been for reasons relating to alcohol. For each substance category, prior substance use 
treatment utilization was much higher among those who would go on to enter treatment within 
one year. 
 After controlling for all of these factors, including prior treatment utilization, the ASSIST 
substance-specific score was found to be significantly associated with entry to treatment within 
one year. Indeed, mean ASSIST scores for those who went on to treatment were 1.75 to 2.5 
times higher than the mean scores of those who did not go on to treatment. Several other results 
complicate this finding. As noted, subjects who went on to treatment were significantly less 
likely to be identified on the ASSIST. This difference was controlled for in the model associating 
ASSIST score and entry to treatment, but it does raise concerns regarding the efficacy of the 
ASSIST for prediction of entry to treatment given that a clinical setting would not necessarily 
have access to previous substance use diagnoses or clinical records from prior SU treatment 
episodes. 
 Examining the sensitivity of the ASSIST score for predicting entry to treatment reveals a 
complex picture. A simple unadjusted model finds that for every 10 points on the ASSIST score 
an opioid user has 30% greater odds for entry to treatment within one year. This effect was 
stronger for alcohol users at 98% increased odds, and 52% for cocaine users. The R2 values for 
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these models reveal that they are accounting for a very small percentage of the total variance, 
indicating that by itself, substance use severity as captured by the ASSIST score accounts for 
only a small amount of the reason these users are entering treatment. Adjustment of these models 
involved incorporation of other known factors. In the case of alcohol and cocaine odds ratios 
were reduced, suggesting that the ASSIST score in the unadjusted model was in some way 
functioning as a surrogate measure for these other known factors; probably prior substance use 
treatment utilization given the results of Table 6. The OR for opioid increased however, 
suggesting that for these users the association of the ASSIST score with entry to post treatment 
was being masked by confounding factors. 
 While the raw ASSIST score was found to be predictive of entry to treatment within one 
year, in a clinical setting risk categories are more commonly used. The association between 
ASSIST score category and risk of one year entry to treatment showed inconsistent 
differentiation within the three substance categories examined. All alcohol and cocaine users 
who fell into the ‘high’, ‘moderate high’, or ‘moderate low’ were more likely than users who fell 
into the ‘Low’ category to go on to substance use treatment within one year, but no significant 
difference was found between these groups separately. Among opioid users only those who fell 
into the ‘high’ or ‘moderate-high’ categories were found to have significantly elevated ORs in 
comparison to those who fell into the ‘low’ category, and differences between these two 
categories were not found to be significant. 
 While adjusted models such as these are important for isolating the association of the 
ASSIST score and one-year entry to treatment, they may be less interpretable in a clinical 
setting. For these purposes we might wish to look at the unadjusted figures to understand the 
differentiation of score categories for prediction of entry to treatment. These results tell a 
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different story. Among opioid users, differentiation among ‘high’ and ‘moderate-high’ scoring 
users appears poor, along with differences between ‘low’ and ‘moderate-low’ users. Power was 
insufficient in either of these cases to demonstrate this lack of differentiation as significant, but 
the simple percentage difference between each set of categories is quite small. These results 
suggest that for this group it might be more beneficial to simply categorize opioid patients as 
‘high’ or ‘low’ risk for the purposes of predicting entry to treatment. Among alcohol users 
differentiation appeared strong for all categories except for ‘High’ and ‘Moderate-High’ 
suggesting that these groups may have similar degrees of treatment utilization. Cocaine users 
showed a less straightforward pattern with strong differentiation only with the ‘Low’ 
categorization, suggesting that the other groups showed similar treatment utilization patterns, 
though this could have been due to insufficient power to detect the effect sizes here, which were 
in some cases moderate. 
Substance Reported Measure Reference Reported OR E-Value 
E-Value  (low 
95%CI) 
Opioids aOR/10 Table 9 1.38 2.10 1.76 
 'High' vs. 'Low' aOR Figure 3 2.80 5.04 2.66 
 'Mod-High' vs 'Low' aOR Figure 3 2.28 3.99 1.49 
Alcohol aOR/10 Table 9 1.53 2.43 2.13 
 'High' vs. 'Low' aOR Figure 3 4.16 7.79 4.01 
 'Mod-High' vs 'Low' aOR Figure 3 3.24 5.93 3.56 
Cocaine/Crack aOR/10 Table 9 1.43 2.21 1.81 
 'High' vs. 'Low' aOR Figure 3 3.19 5.83 2.66 
 'Mod-High' vs 'Low' aOR Figure 3 2.40 4.23 1.64 
Table 11-Selected results and calculated E-Values with confidence intervals 
 The results of this study suggest that the ASSIST substance-specific score may be an 
effective predictor for one year entry to treatment, but these results are limited due to the fact that 
subjects received a brief intervention or referral to treatment depending upon these scores. This 
intervention could also explain the increased treatment utilization observed by those who scored 
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higher on the ASSIST. To better assess this potential confounding effect, Table 11 reports 
several of the principal results from this study along with a calculated E-Value for each, as 
described in a recent paper by VanderWeele and Ding32. Here the authors describe the E-value as 
“a continuous measure of an association’s robustness to potential uncontrolled 
confounding…The higher the E-value, the stronger the confounder associations must be in order 
to explain away the effect.” For example looking to table 11 we see that the adjusted odds ratio 
for an opioid user scoring in the ‘High’ category going on to treatment within one year, as 
compared to an opioid user in the ‘low’ category, was 2.8. Here the E-value33 is 5.04 with a 
lower 95% CI of 2.66, suggesting that the sum total effect of any confounders which would 
explain away this effect would have to have this OR. In this case we know that opioid users 
falling into the ‘high’ score category were given a brief intervention and referred to treatment – 
in order for the confounding effect of this intervention to account for the observed association, 
the effect of this and other confounding effects would have to make users falling into the ‘High’ 
score category about 166 to 400% more likely to enter treatment within one year than users in 
the ‘Low’ score category. This can be difficult to contextualize because few studies so far 
evaluated rates of entry to treatment following brief interventions and referral to treatment34. One 
study reported that among 347 opioid users the odds of users reporting willingness to enter 
treatment were 57% higher among those who participated in an SBIRT program as compared to 
those who did not 35. 
While the association of ASSIST score and one year entry to treatment is limited by the 
potential confounding effect of brief interventions and referral to treatment, other related results 
are less obviously limited by this effect. The identified association between the ASSIST score 
and prior treatment utilization for instance would be unlikely to be susceptible to this 
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confounding effect, as well as the overall association between past and future treatment 
utilization. Differences were also identified in the sensitivity of the ASSIST score category to 
prediction of future treatment utilization across separate substance categories. It is possible that 
this could indicate a difference in the efficacy or consistency of the applied interventions for 
each score category. 
 Regardless of limitations, these results show that the ASSIST substance-specific score 
can indeed be an effective predictor for one year entry to treatment, but this efficacy is relative to 
other potential predictors. Figure 4 shows that the ASSIST score is not the most effective 
predictor of one-year entry to treatment; the number of prior substance use treatments is the most 
important variable for this prediction, followed by whether the subject was identified via the 
ASSIST or not, whether the subject used prescription opioids, heroin, or both, the age of the 
subject, and then the ASSIST score. Currently both opioid type and ASSIST score are captured 
via the ASSIST, but this illustrates the potential utility of asking patients about their prior 
substance use treatment utilization. With the exception of ASSIST Identification status, all of the 
top 10 predictive variables for one-year entry to treatment could be captured by a screening tool 
including the ASSIST, simple demographic questions, and questions regarding the subject’s 
history of prior treatment. 
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